GAMMA Investing LLC Buys 868 Shares of Solventum Co. (NYSE:SOLV)

GAMMA Investing LLC lifted its position in Solventum Co. (NYSE:SOLV) by 35.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,329 shares of the company’s stock after acquiring an additional 868 shares during the period. GAMMA Investing LLC’s holdings in Solventum were worth $220,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Trian Fund Management L.P. boosted its position in shares of Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares in the last quarter. State Street Corp grew its stake in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the period. Geode Capital Management LLC increased its holdings in shares of Solventum by 4.0% in the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after acquiring an additional 128,317 shares in the last quarter. Nuance Investments LLC bought a new stake in shares of Solventum in the second quarter worth about $115,829,000. Finally, Newport Trust Company LLC acquired a new stake in Solventum during the 2nd quarter worth approximately $98,976,000.

Analyst Ratings Changes

Several equities research analysts recently commented on SOLV shares. Piper Sandler boosted their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Morgan Stanley boosted their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Mizuho started coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Finally, Wolfe Research initiated coverage on shares of Solventum in a research note on Thursday, September 26th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $68.29.

Solventum Stock Performance

NYSE SOLV opened at $69.46 on Wednesday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The stock has a 50 day moving average of $69.59 and a 200-day moving average of $64.63. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.